Radiopharm Theranostics Business Summary

Radiopharm Theranostics Ltd (RADX) is a clinical-stage biopharmaceutical company specializing in the development of a multi-platform pipeline of radiopharmaceutical products for diagnostic and therapeutic oncology applications. The company’s business model is currently centered on research and development, generating revenue primarily through R&D tax incentives and modest contract-based service fees, with a long-term strategy focused on milestone-driven licensing and the commercialization of its proprietary assets. Its primary business segments are categorized by its diverse technology platforms, which include nanobodies, monoclonal antibodies, small molecules, and peptides targeting high-unmet-need cancers such as brain metastases (RAD101), HER2-positive tumors (RAD202), and PD-L1-positive lung cancer (RAD204). Within the competitive landscape, Radiopharm distinguishes itself from peers like Telix Pharmaceuticals, Clarity Pharmaceuticals, and Lantheus by intentionally avoiding crowded "me-too" targets like PSMA and FAP, instead positioning itself as a first-in-class innovator in niche radioligand therapy markets. Founded in 2021 by serial biotech entrepreneur Paul Hopper, who serves as Executive Chairman, the company is led by a management team with deep pedigree in nuclear medicine and oncology. CEO and Managing Director Riccardo Canevari previously served as the Chief Commercial Officer of Advanced Accelerator Applications (a Novartis company), where he led global commercial strategy for blockbuster radiopharmaceuticals. The leadership team also includes CFO Phillip A. Hains, Chief Medical Officer Dr. Dimitris Voliotis (formerly of Loxo Oncology at Lilly), and Chief Technical Officer Dr. Thom Tulip. Radiopharm’s strategic position is further bolstered by its joint venture with the MD Anderson Cancer Center, known as Radiopharm Ventures, and a board that includes notable industry figures such as Dr. Leila Alland and recent Scientific Advisory Board appointee Dr. Oliver Sartor, a world-renowned expert in prostate cancer and radioligand therapy.